BNET Industries
Millennium Pharmaceuticals Inc. (MLNM) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $527.5M
- Profit
- Dec 31 2007
- $14.9M
- Market Cap
- May 08 2008
- $8.1B
Latest News and Analysis
EmergingMarketsllc.com: Emerging Equity Alerts.
M2 PRESSWIRE-16 June 2006-Emerging Markets Consulting, LLC.: EmergingMarketsllc.com: Emerging Equity AlertsC1994-2006 M2 COMMUNICATIONS LTD RDATE:16062006 Orlando, FL - Stocks gaining traction in yesterday's trading are Millennium Pharmaceuticals, Inc., (NASDAQ: MLNM), Encysive Pharmaceuticals, Inc., (NASDAQ: ENCY), Discovery Laboratories, Inc., (NASDAQ:...
New Clinical Trial Data Showed the Addition of INTEGRILIN (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone
In this article Millennium Pharmaceuticals, Inc. discusses the CLEAR Platelets Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets trial, the addition of INTEGRILIN, a potent glycoprotein GP IIb-IIIa inhibitor, to a commonly used antiplatelet regimen provided superior platelet inhibition and prevention of heart muscle damage associated with elective...
XOMA and Millennium Announce Initiation of Phase I Clinical Trial of MLN2222 - a.k.a. CAB-2 - a Novel Complement Inhibitor
In this article, XOMA Ltd. and Millennium Pharmaceuticals, Inc. discusses their initiation of a phase I clinical trial with the complement inhibitor MLN2222 (also known as CAB-2). Complement activation is believed to contribute to harmful inflammatory responses to heart bypass surgery that can result in significant complications; MLN2222 is being...
Millennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer Second Clinical Trial With MLN2704
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I/II multiple ascending-dose clinical trial of MLN2704 in patients with metastatic androgen-independent prostate cancer. MLN2704 is designed to deliver the maytansinoid chemotherapeutic agent, DM1, directly to prostate cancer cells through a targeted monoclonal antibody vehicle (T-MAV) that binds...
Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN2704 (formerly known as MLN591DM1) in patients with metastatic androgen-independent prostate cancer. MLN2704 is designed to deliver the maytansanoid chemotherapeutic agent DM1 directly to prostate cancer cells through the MLN591 delivery mechanism, a targeting...
FDA Grants Millennium's MLN341 and MLN518 Fast Track Status
This article encapsulates and gives details about Millennium Pharmaceuticals. Millennium Pharmaceuticals is a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products with a goal of delivering personalized medicine. Millennium Pharmaceuticals informs that the Food...
Millennium Initiates Phase I Clinical Trial of MLN518 in Acute Myeloid Leukemia (AML)
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN518 in patients with Acute Myeloid Leukemia AML. This open-label study is being conducted to assess the tolerability, safety and pharmacokinetic properties of MLN518. The study is being conducted at five U.S. sites in...
Millennium Initiate Phase I Clinical Trial of MLN518 in Acute Myeloid Leukemia (AML)
In this article Millennium Pharmaceuticals, Inc. reveals the initiation of a phase I clinical trial of MLN518 in patients with Acute Myeloid Leukemia AML. This open-label study is being conducted to assess the tolerability, safety and pharmacokinetic properties of MLN518. The study is being conducted at five U.S. sites in...
Waltham, Mass., Venture-Capital Firm Recruits Pharmaceutical Executive.
By Beth Healy, The Boston Globe Knight Ridder/Tribune Business News Apr. 4--Polaris Venture Partners has recruited Millennium Pharmaceuticals executive Alan Crane to be a venture partner at the Waltham firm. Crane has been vice president of corporate development at Millennium, a...
U.S. Bancorp Piper Jaffray Initiates Coverage of Four Leading Genomics Companies
Business Editors NOTE TO EDITORS: The following is an investment opinion issued by U.S. Bancorp Piper Jaffray MINNEAPOLIS--BUSINESS WIRE--May 19, 2000 U.S. Bancorp Piper Jaffray Senior Analyst Thomas Hancock initiated coverage of four companies in his genomics and biotechnology suppliers research universes today: Human Genome Sciences,...
Millennium Announces Findings From a Phase I Clinical Trial of MLN2704 in Progressive, Metastatic Hormone-Refractory Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses their preliminary results from a phase I clinical trial of MLN2704 in patients with progressive metastatic hormone- refractory prostate cancer. The findings from the study indicated that MLN2704 was very well tolerated and produced antitumor activity, including one partial response in a patient...
Millennium and Schering-Plough Initiate Clinical Trial With INTEGRILIN (Eptifibatide) Injection in Early Use Acute Coronary Syndrome Setting
In this article Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation discusses the initiation of a multicenter phase IIIb clinical trial to evaluate the benefit of INTEGRILIN when administered early to high-risk patients experiencing non-ST-segment elevation acute coronary syndrome. The trial, known as EARLY ACS (Early Glycoprotein IIb-IIIa Inhibition in Non-ST-segment Elevation...
Millennium Initiates Phase I Clinical Trial of MLN3897
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN3897, the first compound to enter clinical trials from its inflammation collaboration with Aventis Pharmaceuticals, Inc. MLN3897 (Aventis' compound code: AVE-9897), an orally-administered small molecule, is designed to block CCR1, a chemokine receptor found...
Millennium Initiates Phase I Clinical Trial of MLN1021, a Novel, Oral Factor Xa Inhibitor
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN1021, an orally administered inhibitor of Factor Xa, a critical enzyme in the formation of blood clots. MLN1021 will be investigated for a variety of applications in patients with thrombotic disease, including preventing and...
Millennium Initiates Phase I Clinical Trial of MLN1202
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN1202. MLN1202, a novel humanized monoclonal antibody that blocks the chemokine receptor known as CCR2, is being developed as a potential treatment for patients with rheumatoid arthritis and possibly other inflammatory diseases. The primary...
Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen Independent Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN2704 (formerly known as MLN591DM1) in patients with metastatic androgen-independent prostate cancer. MLN2704 is designed to deliver the maytansanoid chemotherapeutic agent DM1 directly to prostate cancer cells through the MLN591 delivery mechanism, a targeting...
Additional Resources
CORRECTION
Our September feature, "A Merger Made in Heaven," misspelled the name of Stephen Gansler, SVP, HR at Millennium Pharmaceuticals: The Takeda Oncology Company...
Robust Sales of Integrilin, ReoPro and Aggrastat Will Drive the Unstable Angina/Non-ST-Elevation Myocardial Infarction Drug Market
Premium Priced Drug Classes Account for 70 Percent of Market Sales, According to a New Report from Decision Resources WALTHAM, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts robust sales growth in the...
Zacks Analyst Interview Highlights: Genentech, ImClone Systems, Bristol-Myers Squibb and Celgene
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Genentech (NYSE: DNA), ImClone Systems (Nasdaq: IMCL), Bristol-Myers Squibb (NYSE: BMY) and Celgene (Nasdaq: CELG). Get the most recent insight from Zacks Equity Research with the free Profit from the...
MERGER MADE IN HEAVEN
We've all heard horror stories about ugly mergers stifling innovation and crushing employee morale, but Takeda's hands-off melding with Millennium and AstraZeneca's absorption of MedImmune show that it doesn't have to be that way, Matthew Arnold reports: At the newly renamed Millennium Pharmaceuticals: The Takeda Oncology Company,...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Incorporated: 1993
- CEO: Dr. Deborah Dunsire M.D.
Millennium Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines to improve the lives of patients with cancer, inflammatory bowel diseases and other inflammatory diseases. Co.'s VELCADE® (bortezomib) product for Injection, is marketed for the treatment of patients with multiple myeloma who have received at least one prior therapy and for the treatment of Mantle Cell Lymphoma, or MCL, patients who have received at least one prior therapy. Co. distributes VELCADE in the U.S. through a sole-source open access distribution model where Co. sells directly to an independent third party who in turn distributes to the wholesaler base.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Millennium Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Kenneth E. Weg
Chairman
Dr. Jeffrey M. Leiden M.D., Ph
Mr. A. Grant Heidrich III
Vice-Chairman
Dr. Anthony H. Wild Ph.D.
Mr. Mark J. Levin
Dr. Charles J. Homcy M.D.
Dr. Raju S. Kucherlapati Ph.D.
Mr. Norman C. Selby
Dr. Deborah Dunsire M.D.
Mr. Robert F. Friel
Contact Information
40 Landsdowne Street
Cambridge, MA
617 679-7000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
